文献速递白血病

CCT241736 对 quizartinib 耐药 FLT3-ITD 急性髓系白血病细胞敏感

Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
PubMed 文献 · Blood Adv · 2020-01-01

FLT3-ITD 是急性髓系白血病常见突变,与高复发率和差生存相关,FLT3 抑制剂耐药成为临床问题。CCT241736 是口服生物利用的双重 FLT3/Aurora 激酶抑制剂,对携带继发 FLT3-TKD 突变的 FLT3-ITD+ 细胞保持体外活性,并在体内模型和原代样本中显示疗效。

要点

  • FLT3-ITD+ 伴继发 FLT3-TKD 突变细胞对 quizartinib 和 sorafenib 相对耐药,但对 CCT241736 不耐药。
  • CCT241736 在 FLT3-ITD 和 FLT3-ITD-TKD 人肿瘤异种移植模型中抑制肿瘤生长。
  • CCT241736 在包括 quizartinib 耐药的原代 AML 样本中诱导凋亡,机制涉及抑制 FLT3 和 Aurora 激酶。

核心结论

  • CCT241736 是口服生物利用、选择性且强效的 FLT3 和 Aurora 激酶双重抑制剂。
  • CCT241736 对 quizartinib 耐药的 FLT3-ITD 急性髓系白血病细胞具有敏感性,是临床候选药物。

研究设计与样本

  • 研究采用体外细胞实验、体内人肿瘤异种移植模型和 AML 患者原代样本。

主要发现

  • 携带继发 FLT3-TKD 突变的 FLT3-ITD+ 细胞对 quizartinib 和 sorafenib 有高体外相对耐药性,但对 CCT241736 无此耐药性。
  • CCT241736 在 FLT3-ITD 和 FLT3-ITD-TKD 人肿瘤异种移植模型的疗效研究中抑制肿瘤生长。
  • CCT241736 在包括 quizartinib 耐药疾病的 AML 患者原代样本中确认疗效,通过抑制 FLT3 和 Aurora 激酶诱导凋亡。

临床怎么用

  • 对于 FLT3-ITD 伴 FLT3-TKD 突变且对 quizartinib 耐药的 AML 患者,CCT241736 可能提供治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Internal tandem duplication of FLT3 (FLT3-ITD) is one of the most common somatic mutations in acute myeloid leukemia (AML); it causes constitutive activation of FLT3 kinase and is associated with high relapse rates and poor survival. Small-molecule inhibition of FLT3 represents an attractive therapeutic strategy for this subtype of AML, although resistance from secondary FLT3 tyrosine kinase domain (FLT3-TKD) mutations is an emerging clinical problem. CCT241736 is an orally bioavailable, selective, and potent dual inhibitor of FLT3 and Aurora kinases. FLT3-ITD+ cells with secondary FLT3-TKD mutations have high in vitro relative resistance to the FLT3 inhibitors quizartinib and sorafenib, but not to CCT241736. The mechanism of action of CCT241736 results in significant in vivo efficacy, with inhibition of tumor growth observed in efficacy studies in FLT3-ITD and FLT3-ITD-TKD human tumor xenograft models. The efficacy of CCT241736 was also confirmed in primary samples from AML patients, including those with quizartinib-resistant disease, which induces apoptosis through inhibition of both FLT3 and Aurora kinases. The unique combination of CCT241736 properties based on robust potency, dual selectivity, and significant in vivo activity indicate that CCT241736 is a bona fide clinical drug candidate for FLT3-ITD and TKD AML patients with resistance to current drugs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moore AS, Faisal A, Mak GWY, et al. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Adv. 2020. PMID: 32282883. doi:10.1182/bloodadvances.2019000986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。